COL18A1 and rheumatoid arthritis: Here, we show that in addition to its anti-inflammatory properties, tofacitinib inhibits angiogenesis by reducing the pro-angiogenic factors and elevating the levels of the anti-angiogenic factor endostatin in RA patients.